History

2000 The European Molecular Biology Laboratory [» EMBL] in Heidelberg, Germany spins out Cellzome. Initial focus is the detailed analysis of the organization of the proteome of both yeast and mammalian cells.
2001 Completion Series B financing of € 34 million. Acquisition of GSK's CellMap Unit and foundation of Cellzome UK.
2002 Publication of the "Functional Organization of the Yeast Proteome by Systematic Analysis of Protein Complexes" in Nature - the first scientific validation of Cellzome's technology and the "Faculty of 1000" all time #1 paper in genetics and genomics (Jan 2004).
2003 Completion of Series C funding of € 30 million. Latter half of the year, entered two partnerships with pharmaceutical companies, Johnson & Johnson PRD and Bayer HealthCare.
2004 Cellzome published "A physical and functional map of the human TNF-α/NF-κB signal transduction pathway" in Nature Cell Biology.
Tim Edwards appointed CEO and President. A significant research collaboration signed with Novartis to identify new drug targets and leads in a variety of disease areas.
2005 Drug discovery partnership agreed with Ortho-McNeil Pharmaceutical / Johnson & Johnson PRD for the identification of new medicines for the treatment of Alzheimer's Disease.
Novartis collaboration expanded to provide further analyses of both target candidates and signalling aspects of certain disease pathways.
Drug discovery collaboration with Argenta Discovery to extend and complement Cellzome's capabilities.
Cellzome and Graffinity Pharmaceuticals awarded a € 2.2m grant from the German Ministry of Research and Education for the discovery of novel treatments for disorders of the immune system.
2006 Cellzome and the European Molecular Biology Laboratory (EMBL) published the first genome-wide screen for protein complexes in Nature.
Collaboration with BioFocus DPI, the service division of Galapagos, giving Cellzome access to BioFocus DPI's SoftFocus® kinase libraries and enabling Kinobeads™-based screens.
Extension of collaboration with Novartis for further 2 years.
Extension of collaboration with Johnson & Johnson in Alzheimer's Disease to March 2008.
2007 First milestone payment received from Johnson & Johnson for selection of lead molecule.
Publication of Kinobeads™ Technology: new targets for Glivec identified.
Cellzome's CEO Tim Edwards appointed to the Board of the UK's BioIndustry Association.
Cellzome Establishes Scientific Advisory Board.
2008 Cellzome appoints Dr. Jane Dancer as VP Business Development.